i-Port Advance system lowers blood sugar, hypoglycemic episodes in T1 diabetes: Study

Written By : Medha Baranwal |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2021-04-10T08:15:26+05:30 | Updated On 10 April 2021 8:13 AM IST

Saudi Arabia: The use of i-Port Advance system may lower both blood sugar levels, hypoglycemic episodes, and raise patients' satisfaction levels in type 1 diabetes (T1D) patients, according to a recent study in the journal Diabetes & Metabolic Syndrome: Clinical Research & Reviews.

Ayman A. Al Hayek, Department of Endocrinology and Diabetes, Diabetes Treatment Center, Prince Sultan Military Medical City, Riyadh, Saudi Arabia, and colleagues aimed to determine the efficacy of i-Port Advance system on patient satisfaction and glycemic control among patients with type 1 diabetes.

For this purpose, the researchers performed a prospective study among 73 patients with T1D (13–29 years) at Prince Sultan Military Medical City, Riyadh, Saudi Arabia. Demographic data were collected at baseline and clinical characteristics were collected at baseline and 12 weeks.

Patients' responses to Morisky Medication Adherence Scale (MMAS-8) and Insulin Delivery Satisfaction Survey (IDSS) were recorded at baseline and 12 weeks after initiating the i-Port Advance system.

Key findings of the study include:

At 12 weeks, significant improvement was evident in the IDSS subscales, which comprises the IDSS effective, burdensome, and IDSS inconvenient, with the total baseline IDSS score being 2.6 ± 0.42, and at 12 weeks being 3.7 ± 0.72.
The MMAS total score at baseline was 4.6 ± 1.2, and at 12 weeks, it increased to 6.4.
HbA1c level was 8.4% at baseline and decreased to 7.9% at 12 weeks. The total daily dose of insulin at baseline registered 0.9 ± 0.13, which declined to 0.8 ± 0.12 at 12 weeks.
Fasting blood sugar value was 197 ± 23.4 at baseline, which dropped to 182 ± 24.5 at 12 weeks; and the postprandial glucose at baseline was 195 ± 21.4 and declined to 177 ± 19.2 at 12 weeks.
The hypoglycemic episodes revealed a noteworthy reduction after the i-Port Advance system usage.

"Use of i-Port Advance system was found to raise the patients' satisfaction levels and lower both the hypoglycemic episodes as well as the HbA1c levels," wrote the authors.

Reference:

The study titled, "Efficacy of i-Port Advance system on patients satisfaction and glycemic control among patients with type 1 diabetes in Saudi Arabia," is published in the journal Diabetes & Metabolic Syndrome: Clinical Research & Reviews.

DOI: https://www.sciencedirect.com/science/article/abs/pii/S1871402121001028

Type 1 diabetesi-Port Advance Systemglycemic controlblood sugarhypoglycemia

Source : Diabetes & Metabolic Syndrome: Clinical Research & Reviews

Medha Baranwal

MSc. Biotechnology

Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751